Matrix Metallopeptidase 16 (Membrane-inserted) (MMP16) (Catalytic Domain) antibody

Details for Product No. ABIN181342
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms Mt3mmp, MT3-MMP, Mt3-mmp, C8orf57, MMP-X2, MT-MMP2, MT-MMP3
Epitope
Catalytic Domain
(9), (4), (3), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(69), (36), (34), (18), (18), (17), (17), (1), (1)
Host
Rabbit
(69), (2), (1)
Clonality
Polyclonal
Conjugate
Un-conjugated
(1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
(47), (24), (19), (16), (16), (15), (10), (4), (2), (1), (1), (1)
Pubmed 4 references available
Catalog no. ABIN181342
Quantity 0.5 mg
Price
595.32 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Discontinued
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen A synthetic peptide from the catalytic domain of human MMP-16 / MT3-MMP.
Specificity This antibody detects MMP-16.
Purification Protein A chromatography
Alternative Name MMP-16
Background MMPs are a group of enzymes involved in matrix degradation. Of the sixteen members of matrix metalloproteinase family ten exist in soluble form whereas MT-MMPs exist as integral membrane proteins. MT1-MMP, MT2-MMP, MT3- MMP also known as MMP14, MMP15, MMP16 respectively contain a C-terminal transmembrane domain anchoring them to the cell surface. They have an 8 amino acid insert in their catalytic domain. MT1-MMP cleaves progelatinase A (MMP-2) and progelatinase B to their active forms. MT1-MMP gets activated through the membrane plasmin cascade. It binds to TIMP-2 first and then to MMP-2 forming a trimer. It cleaves the pro-MMP-2 to its active form. MT3-MMP may play a minor role in activation of pro-MMP-2 to its active form.
Alternate names: MMP-X2, MMP16, MMPX2, Matrix metalloproteinase-16, Membrane-type-3 matrix metalloproteinase
Cellular Localization: Cell membrane and cytoplasmic
Gene ID 4325
NCBI Accession NP_005932.2
UniProt P51512
Research Area Extracellular Matrix
Application Notes Immunohistology (formalin/paraffin: 10-20g/ml for 30 min at RT, Staining offormalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for10-20 min followed by cooling at RT for 20 min, Recommended positive control: Placenta). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer 10 mM PBS, pH 7.4, with 0.2 % BSA & 0.09 % sodium azide.
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody at 2 - 8 °C up to one month or in aliquots at -20 °C for longer.
Expiry Date 12 months
Supplier Images
anti-Matrix Metallopeptidase 16 (Membrane-inserted) (MMP16) (Catalytic Domain) antibody anti-Matrix Metallopeptidase 16 (Membrane-inserted) (MMP16) (Catalytic Domain) antibody
Background publications Takino, Sato, Shinagawa et al.: "Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family." in: The Journal of biological chemistry, Vol. 270, Issue 39, pp. 23013-20, 1995 (PubMed).

Strongin, Collier, Bannikov et al.: "Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease." in: The Journal of biological chemistry, Vol. 270, Issue 10, pp. 5331-8, 1995 (PubMed).

Sato, Takino, Okada et al.: "A matrix metalloproteinase expressed on the surface of invasive tumour cells." in: Nature, Vol. 370, Issue 6484, pp. 61-5, 1994 (PubMed).

Ueno, Nakamura, Inoue et al.: "Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas." in: Cancer research, Vol. 57, Issue 10, pp. 2055-60, 1997 (PubMed).

Hosts (69), (2), (1)
Reactivities (69), (36), (34), (18), (18), (17), (17), (1), (1)
Applications (47), (24), (19), (16), (16), (15), (10), (4), (2), (1), (1), (1)
Conjugates (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (9), (4), (3), (3), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1)
back to top